Compounds > aspirin
Page last updated: 2024-10-23

aspirin and Wet Macular Degeneration

aspirin has been researched along with Wet Macular Degeneration in 7 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Wet Macular Degeneration: A form of RETINAL DEGENERATION in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision.

Research Excerpts

ExcerptRelevanceReference
"Aspirin use was not associated significantly with progression to late AMD or its subtypes in either the AREDS or AREDS2."2.90The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies: Age-Related Eye Disease Study 2 Report No. 20. ( Agrón, E; Aronow, ME; Chew, EY; Christen, WG; Clemons, TE; Keenan, TD; Wiley, HE, 2019)
"Most retinal or subretinal hemorrhages in eyes enrolled in CATT were less than 1 DA."2.82Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials. ( Ahmed, O; Daniel, E; Grunwald, JE; Maguire, MG; Martin, DF; Ying, GS, 2016)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Lee, WA1
Yang, YK1
Cheng, CL1
Rim, TH1
Yoo, TK1
Kwak, J1
Lee, JS1
Kim, SH1
Kim, DW1
Kim, SS1
Keenan, TD1
Wiley, HE1
Agrón, E1
Aronow, ME1
Christen, WG1
Clemons, TE1
Chew, EY1
Sobrin, L1
Seddon, JM1
de Jong, PT2
Wang, JJ1
Fletcher, AE2
Ying, GS1
Maguire, MG1
Daniel, E1
Grunwald, JE1
Ahmed, O1
Martin, DF1
Chakravarthy, U1
Rahu, M1
Seland, J1
Soubrane, G1
Topouzis, F1
Vingerling, JR1
Vioque, J1
Young, I1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)[NCT00593450]Phase 31,208 participants (Actual)Interventional2008-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Area of Lesion

(NCT00593450)
Timeframe: at 1 Year

Interventionmm^2 (Mean)
1-Lucentis Monthly6.6
2-Avastin Monthly6.5
3-Lucentis as Needed7.3
4-Avastin as Needed7.0

Area of Lesion Change From Baseline

(NCT00593450)
Timeframe: Baseline and 1 Year

Interventionmm^2 (Mean)
1-Lucentis Monthly-0.1
2-Avastin Monthly0.3
3-Lucentis as Needed0.6
4-Avastin as Needed1.3

Average Cost of Drug/Patient

(NCT00593450)
Timeframe: at 1 Year

InterventionUS dollars per patient (Mean)
1-Lucentis Monthly23400
2-Avastin Monthly595
3-Lucentis as Needed13800
4-Avastin as Needed385

Change From Baseline in Visual-acuity Score (Continuous)

"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline.~In this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement." (NCT00593450)
Timeframe: Baseline and 1 Year

InterventionNo. of Letters (Mean)
1-Lucentis Monthly8.5
2-Avastin Monthly8.0
3-Lucentis as Needed6.8
4-Avastin as Needed5.9

Change in Diastolic Blood Pressure From Baseline

(NCT00593450)
Timeframe: Baseline and 1 Year

Interventionmm Hg (Mean)
1-Lucentis Monthly-0.9
2-Avastin Monthly-1.4
3-Lucentis as Needed-1.9
4-Avastin as Needed-2.1

Change in Systolic Blood Pressure From Baseline

(NCT00593450)
Timeframe: Baseline and 1 Year

Interventionmm Hg (Mean)
1-Lucentis Monthly-2.1
2-Avastin Monthly-5.4
3-Lucentis as Needed-5.2
4-Avastin as Needed-4.5

Number of Treatments

Cumulative over the 1 year of trial (NCT00593450)
Timeframe: 1 Year

InterventionNumber of Treatments (Mean)
1-Lucentis Monthly11.7
2-Avastin Monthly11.9
3-Lucentis as Needed6.9
4-Avastin as Needed7.7

Retinal Thickness Plus Subfoveal-fluid Thickness at Fovea

(NCT00593450)
Timeframe: at 1 Year

Interventionμm (Mean)
1-Lucentis Monthly152
2-Avastin Monthly172
3-Lucentis as Needed166
4-Avastin as Needed172

Retinal Thickness Plus Subfoveal-fluid Thickness Change From Baseline at Fovea

(NCT00593450)
Timeframe: Baseline and 1 Year

Interventionμm (Mean)
1-Lucentis Monthly-100
2-Avastin Monthly-79
3-Lucentis as Needed-81
4-Avastin as Needed-79

Total Thickness at Fovea

(NCT00593450)
Timeframe: at 1 Year

Interventionμm (Mean)
1-Lucentis Monthly266
2-Avastin Monthly300
3-Lucentis as Needed294
4-Avastin as Needed308

Total Thickness Change From Baseline at Fovea

(NCT00593450)
Timeframe: Baseline and 1 Year

Interventionμm (Mean)
1-Lucentis Monthly-196
2-Avastin Monthly-164
3-Lucentis as Needed-168
4-Avastin as Needed-152

Visual-acuity Score and Snellen Equivalent (Continuous)

"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.~In this study, the outcome VA score is ranged from 0 to 97, with the higher score the better visual acuity." (NCT00593450)
Timeframe: at 1 Year

InterventionNo. of Letters (Mean)
1-Lucentis Monthly68.8
2-Avastin Monthly68.4
3-Lucentis as Needed68.4
4-Avastin as Needed66.5

Change From Baseline Visual-acuity Score (Frequency)

(NCT00593450)
Timeframe: Baseline and 1 Year

,,,
InterventionParticipants (Number)
Increase of ≥15 lettersIncrease of 5-14 lettersChange of ≤4 lettersDecrease of 5-14 lettersDecrease of ≥15 letters
1-Lucentis Monthly9790621916
2-Avastin Monthly8398501816
3-Lucentis as Needed71103752313
4-Avastin as Needed7690592323

Dye Leakage on Angiogram

(NCT00593450)
Timeframe: at 1 Year

,,,
InterventionParticipants (Number)
AbsentPresentData missing
1-Lucentis Monthly1679720
2-Avastin Monthly15310012
3-Lucentis as Needed13313715
4-Avastin as Needed11114515

Fluid on Optical Coherence Tomography

(NCT00593450)
Timeframe: at 1 Year

,,,
InterventionParticipants (Number)
AbsentPresentData missing
1-Lucentis Monthly1241519
2-Avastin Monthly691888
3-Lucentis as Needed6820314
4-Avastin as Needed522145

Visual-acuity Score and Snellen Equivalent (Frequency)

(NCT00593450)
Timeframe: at 1 Year

,,,
InterventionParticipants (Number)
83-97 letters, 20/12-2068-82 letters, 20/25-4053-67 letters, 20/50-8038-52 letters, 20/100-160≤37 letters, ≤20/200
1-Lucentis Monthly42149522318
2-Avastin Monthly45134472118
3-Lucentis as Needed38141662317
4-Avastin as Needed40127572423

Trials

2 trials available for aspirin and Wet Macular Degeneration

ArticleYear
The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies: Age-Related Eye Disease Study 2 Report No. 20.
    Ophthalmology, 2019, Volume: 126, Issue:12

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dis

2019
Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Ophthalmology, 2016, Volume: 123, Issue:2

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Bevacizumab; Cardiovascul

2016

Other Studies

5 other studies available for aspirin and Wet Macular Degeneration

ArticleYear
Risk of age-related macular degeneration in aspirin users and non-aspirin users: A population-based cohort study in Taiwan.
    Pharmacoepidemiology and drug safety, 2021, Volume: 30, Issue:2

    Topics: Angiogenesis Inhibitors; Aspirin; Cohort Studies; Humans; Incidence; Middle Aged; Retrospective Stud

2021
Long-Term Regular Use of Low-Dose Aspirin and Neovascular Age-Related Macular Degeneration: National Sample Cohort 2010-2015.
    Ophthalmology, 2019, Volume: 126, Issue:2

    Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male;

2019
Regular aspirin use and risk of age-related macular degeneration.
    American journal of ophthalmology, 2013, Volume: 156, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Risk Factors; Wet Macular Degeneration

2013
Aspirin use and aging macula disorder.
    JAMA ophthalmology, 2014, Volume: 132, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Risk Assessment;

2014
Associations between aspirin use and aging macula disorder: the European Eye Study.
    Ophthalmology, 2012, Volume: 119, Issue:1

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cholesterol; Cross-

2012